Trials / Unknown
UnknownNCT04383353
Pan-canceR Early DetectIon projeCT
Burning Rock Pan-canceR Early DetectIon projeCT (PREDICT): a Prospective, Multicenter Study to Develop and Validate the Performance of a cfDNA Methylation Based Model on Early Cancer Detection
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 14,026 (estimated)
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
PREDICT is a prospective, multi-center study for the early detection of pan-cancer through cell-free DNA (cfDNA) methylation based model, in which approximately 14,000 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers or benign diseases, along with non-tumor (healthy) individuals through a two-stage approach. The sensitivity and specificity of the model in cancer early detection will be evaluated, and the accuracy of the identification for tissue of origin will be obtained.
Conditions
Timeline
- Start date
- 2020-07-21
- Primary completion
- 2022-10-01
- Completion
- 2023-03-01
- First posted
- 2020-05-12
- Last updated
- 2020-07-22
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04383353. Inclusion in this directory is not an endorsement.